EPA:ALSEN - Euronext Paris - Matif - FR0012596468 - Common Stock - Currency: EUR
EPA:ALSEN (4/25/2025, 7:00:00 PM)
0.2092
+0.05 (+34.53%)
The current stock price of ALSEN.PA is 0.2092 EUR. In the past month the price decreased by -54.91%. In the past year, price decreased by -70.37%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.41 | 294.36B | ||
1ABBV.MI | ABBVIE INC | 18.65 | 294.00B | ||
AMG.DE | AMGEN INC | 14.24 | 133.58B | ||
GIS.DE | GILEAD SCIENCES INC | 13.7 | 116.27B | ||
1GILD.MI | GILEAD SCIENCES INC | 22.33 | 112.99B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1665.96 | 111.35B | ||
ARGX.BR | ARGENX SE | 355.92 | 33.03B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 22.07B | ||
IDP.DE | BIOGEN INC | 7.21 | 15.30B | ||
0QF.DE | MODERNA INC | N/A | 9.33B | ||
1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.57B |
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 63 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
SENSORION SA
375, rue du Professeur Joseph Blayac
Montpellier OCCITANIE FR
Employees: 61
Company Website: https://www.sensorion-pharma.com/
Investor Relations: http://sensorion.com/en/investors/
Phone: 33467207730
The current stock price of ALSEN.PA is 0.2092 EUR. The price increased by 34.53% in the last trading session.
The exchange symbol of SENSORION SA is ALSEN and it is listed on the Euronext Paris - Matif exchange.
ALSEN.PA stock is listed on the Euronext Paris - Matif exchange.
12 analysts have analysed ALSEN.PA and the average price target is 2.21 EUR. This implies a price increase of 956.42% is expected in the next year compared to the current price of 0.2092. Check the SENSORION SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SENSORION SA (ALSEN.PA) has a market capitalization of 62.90M EUR. This makes ALSEN.PA a Micro Cap stock.
SENSORION SA (ALSEN.PA) currently has 61 employees.
The Revenue of SENSORION SA (ALSEN.PA) is expected to grow by 17.02% in the next year. Check the estimates tab for more information on the ALSEN.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALSEN.PA does not pay a dividend.
SENSORION SA (ALSEN.PA) will report earnings on 2025-09-16.
SENSORION SA (ALSEN.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
ChartMill assigns a fundamental rating of 3 / 10 to ALSEN.PA. While ALSEN.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ALSEN.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 55.21% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.09% | ||
ROE | -36% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 87% to ALSEN.PA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 11.11% and a revenue growth 17.02% for ALSEN.PA